US Biomaterials in Healthcare Market Report 2022 to 2030

US Biomaterials in Healthcare Market Analysis

$ 3999

The US biomaterials in the healthcare market are projected to grow from $65.6 Bn in 2022 to $153.4 Bn by 2030, registering a CAGR of 11.2% during the forecast period of 2022-30. Chronic diseases such as cardiovascular disease, cancer, and diabetes are on the rise in the US. The market is highly competitive, with several key players, including BASF SE, DSM NV, Invibio Ltd., Carpenter Technology Corporation, Evonik Industries AG, and Royal DSM. These companies invest heavily in research and development to develop new biomaterials and improve the performance of existing ones.

ID: IN10USMD003 CATEGORY: Medical Devices GEOGRAPHY: US AUTHOR: Shivam Zalke

Buy Now

US Biomaterials in Healthcare Market Executive Summary

According to projections, the US biomaterials market for healthcare would increase from $65.6 Bn in 2022 to $153.4 Bn in 2030, growing at a CAGR of 11.2% during the forecast period of 2022-30.

The term "biomaterials" in the US healthcare industry refers to the use of biocompatible materials in implants and medical devices that may be utilised to replace or improve sick or damaged tissues or organs. Moreover, medications or other therapeutic agents may be delivered to particular bodily parts via biomaterials. The prevalence of chronic illnesses is rising, the population is ageing, and biomaterials technological breakthroughs are all driving forces in the industry.

Based on type, application, and end-user, the US biomaterials market in the healthcare industry may be divided. Metals, ceramics, polymers, and composites are examples of different kinds of biomaterials.

Few of the medical fields where biomaterials are used:

Cardiovascular
Orthopaedic
Dental
Wound care
Ophthalmology
Plastic surgery

Hospitals, clinics, and research facilities are some of the final customers of biomaterials in the healthcare industry.

There are a number of significant competitors in the industry, including BASF SE, DSM NV, Invibio Ltd., Carpenter Technology Corporation, Evonik Industries AG, and Royal DSM. The market is very competitive. These businesses make significant investments in R&D to create novel biomaterials and enhance the functionality of ones that already exist.

By guaranteeing the safety and effectiveness of biomaterials used in medical devices and implants, regulatory organisations like the Food and Drug Administration (FDA) play a vital role in the biomaterials market for the healthcare industry. To assure the safety and efficacy of biomaterials used in medical devices, the FDA has devised a strict approval procedure that calls for intensive research and clinical studies. As a result, the regulatory environment may provide a substantial barrier to entry for new competitors in the biomaterials market for healthcare.

us biomaterials in healthcare market analysis

Market Dynamics

Growth Drivers

Many important variables, such as the following, are what drive the US biomaterials in the healthcare market:

Chronic illnesses are becoming more prevalent in the US, including diabetes, cancer, and cardiovascular disease. Since they may be utilised to replace or supplement damaged tissues or organs, biomaterials are being employed more often in the treatment of various illnesses.
Increasingly older population: The US's ageing population is another factor increasing the need for biomaterials in the healthcare sector. People are more prone to chronic diseases that need medical attention as they become older. With elderly persons, orthopaedic and cardiovascular applications often employ biomaterials.
Technical developments: The industry is also being driven by developments in biomaterials technology, such as the creation of novel materials and better production processes. In comparison to earlier generations of biomaterials, new biomaterials are now being produced that function better and are more biocompatible.
Demand for less invasive treatments is rising, which is also boosting the need for biomaterials in the healthcare industry. Since they may be given to particular body regions and eliminate the need for more invasive operations, biomaterials are being utilised more often in minimally invasive treatments including laparoscopic surgery and catheter-based therapies.
Increasing healthcare costs: The US healthcare system continues to spend more money, which is fueling demand for biomaterial-infused medical devices and implants. Devices that are economical and might lessen the need for more costly procedures are increasingly needed as healthcare costs rise.

Competitive Landscape

Key Players

There are many key players in the US biomaterials in the healthcare market, including:

Johnson & Johnson
Zimmer Biomet
Medtronic
Abbott Laboratories
Stryker Corporation
Baxter International
Boston Scientific
DSM Biomedical
Invibio
Evonik Industries

Healthcare Policies and Regulatory Landscape

To assure patient safety and product efficacy, the US healthcare regulations and regulatory environment for biomaterials in healthcare are complicated and heavily regulated. The following are some of the main guidelines and laws regulating the use of biomaterials in healthcare:

FDA Regulations: Via a rigorous premarket clearance procedure, the US Food and Drug Administration (FDA) controls medical devices and biomaterials used in healthcare. Before biomaterials are utilised in implants or medical devices, the FDA evaluates them for safety and efficacy.
Good Manufacturing Practices: To guarantee that biomaterials used in healthcare are of the highest quality and consistent with their intended purpose, they must be produced in accordance with GMP laws.
Biocompatibility Requirements: To be utilised in medical procedures, biomaterials must be biocompatible, which implies they must not have any negative effects on live tissue. The testing specifications for determining the biocompatibility of medical devices are outlined in the ISO 10993 set of standards.
HIPAA, or the Health Insurance Portability and Accountability Act, is a federal legislation that regulates the confidentiality and privacy of patient health information. To safeguard patient privacy, healthcare professionals and producers of biomaterials and medical devices are required to adhere to HIPAA standards.
Medicare Coverage: Medicare is a government health insurance programme that provides coverage to qualified seniors and those with certain disabilities who are over 65. If they are determined to be medically essential, Medicare will pay for certain medical equipment and treatments, including those that use biomaterials.

The regulatory framework for biomaterials in healthcare in the US and US healthcare regulations as a whole is created to guarantee patient safety and product efficacy. It may be time-consuming and expensive for manufacturers of medical devices and biomaterials to bring their goods to market because of the stringent rules and regulations that must be followed, but it ultimately helps patients and the healthcare sector as a whole.

1. Executive Summary
1.1 Device Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Regulatory Landscape for Medical Device
1.6 Health Insurance Coverage in Country
1.7 Type of Medical Device
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

US Biomaterials in Healthcare Market Segmentation

By Type (Revenue, USD Billion):

Based on type, the market is segmented into Metallic Biomaterials, Polymeric Biomaterials, Ceramic Biomaterials, and Natural Biomaterials. The Metallic Biomaterials segment accounted for the largest share of the US market in 2019. The growing geriatric population USly is expected to drive growth for this segment.

Metallic Biomaterials
- Stainless Steel
- Titanium & Titanium Alloys
- Cobalt-Chrome Alloys
- Gold
- Silver
- Magnesium
Polymeric Biomaterials
- Polymethylmethacrylate
- Polyethylene
- Polyester
- Silicone Rubber
- Nylon
- Polyetheretherketone
- Other Polymeric Biomaterials
Ceramics
- Calcium Phosphate
- Zirconia
- Aluminum Oxide
- Calcium Sulfate
- Carbon
- Glass
Natural Biomaterials
- Hyaluronic Acid
- Collagen
- Gelatin
- Fibrin
- Cellulose
- Chitin
- Alginates
- Silk

By Application (Revenue, USD Billion):

The cardiovascular, orthopaedic, dental, plastic surgery, wound healing, tissue engineering, ophthalmology, neurological/CNS, and other applications segments are made up of the biomaterials market. The market category for wound healing is anticipated to have the highest CAGR in 2019. The market will increase as a result of factors including expanding healthcare infrastructure, a large population pool, a rising diabetic population, and rising healthcare spending. Surgical Guides

Cardiovascular
- Catheters
- Stents
- Implantable Cardiac Defibrillators
- Pacemakers
- Sensors
- Heart Valves
- Vascular Grafts
- Guidewires
- Others
Orthopedic
- Joint Replacement
  - Knee Replacement
  - Hip Replacement
  - Shoulder Replacement
  - Others
- Viscosupplementation
- Bioresorbable Tissue Fixation
- Spine
  - Spinal Fusion Surgeries
  - Minimally Invasive Fusion Surgeries
  - Motion Preservation & Dynamic Stabilization Surgeries
    - Pedicle-Based Rod Systems
    - Interspinous Spacers
    - Artificial Discs
- Fracture Fixation Devices
  - Bone Plates
  - Screws
  - Pins
  - Rods
  - Wires
- Synthetics Bone Grafts
Ophthalmology
- Contact Lenses
  - Intraocular Lenses
  - Functional Replacement of Ocular Tissues
  - Synthetic Corneas
  - Others
Dental
- Dental Implants
- Dental Bone Grafts & Substitutes
- Dental Membranes
- Tissue Regeneration
Plastic Surgery
- Soft-Tissue Fillers
- Craniofacial Surgery
Wound Healing
- Wound Closure Devices
  - Sutures
  - Staples
- Surgical Hemostats
- Internal Tissue Sealants
- Adhesion Barriers
- Hernia Meshes
Tissue Engineering
- Scaffolds for Regenerative Medicine
- Nanomaterials for Biosensing
- Tailoring of Inorganic Nanoparticles
Neurological/Central Nervous System Applications
- Shunting Systems
- Cortical Neural Prosthetics
- Hydrogel Scaffolds for CNS Repair
- Neural Stem Cell Encapsulation
Other Applications
- Drug Delivery Systems
- Gastrointestinal Applications
- Bariatric Surgery
- Urinary Applications

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.